Sirakova V, Penkov N, Kaponov Kh
Vutr Boles. 1988;27(6):21-5.
The antihypertensive and hemodynamic efficacy of Betaloc (Egys-Hungary) was studied in 30 hypertensive patients in the II stage of the disease. The drug was applied in a single daily dose of 100 mg in the course of 6 months. The systolic and diastolic pressure and the heart rate decreased reliably (p less than 0.0001) at the end of the first month. The stroke volume increased (p less than 0.045) at the end of the sixth month but the minute volume and the cardiac index did not change (p greater than 0.32). The peripheral vascular resistance dicreased reliably (p less than 0.02) at the end of the sixth month--the degree depending on the initial type of circulation--and it determined the longstanding antihypertensive efficacy of Betaloc. No untoward reactions were registered.
对30例二期高血压患者研究了倍他乐克(匈牙利伊盖什制药厂生产)的降压及血液动力学疗效。在6个月疗程中,每日单次给药100毫克。第一个月末,收缩压、舒张压和心率均显著下降(p<0.0001)。第六个月末,每搏输出量增加(p<0.045),但每分输出量和心脏指数未改变(p>0.32)。第六个月末,外周血管阻力显著降低(p<0.02),降低程度取决于初始循环类型,这也决定了倍他乐克的长期降压疗效。未发现不良反应。